JUPITER - Crestor 20mg versus placebo in prevention of Cardiovascular (CV) events
Study identifier:D3560L00030
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects with Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein
Medical condition
elevated High-sensitivity C-Reactive Protein (hsCRP)
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin
Sex
All
Actual Enrollment
17802
Study type
Interventional
Age
50 Years +
Date
Study Start Date: 01 Feb 2003
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verification:
Verified 01 Feb 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Rosuvastatin Rosuvastatin 20 mg once daily | Drug: Rosuvastatin Oral Other Name: Crestor |
| Placebo Comparator: Placebo Placebo once daily | Other: Placebo Oral |
Contacts
Contact
AstraZeneca Information Center Telephone: 800-236-9933, (US - 8a-7p EST)
-
Investigators
Principal Investigator
Judith Hsia
AstraZeneca
